Notice of Proposed Sale · 144

Contineum Therapeutics, Inc.

CTNMNASDAQEQUITYCurrent

Notice of Proposed Sale

Filed Jul 1, 2026Accepted Jul 1, 2026, 4:34 PM EDTFiling CIK 1861550Accession 0001950047-26-006723

View company →Permanent SEC source ↗

Structured filing — 144

primary_doc.xml

Open full document ↗

Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.

Proposed-sale notice

Issuer: Contineum Therapeutics, Inc.
Issuer CIK: 0001855175
SEC file number: 001-42001
Phone: 8583335280
Person for whose account securities are to be sold: Daniel Lorrain
Relationships to issuer: Officer
Street: 3565 General Atomics Court, Suite 200
City: San Diego
State / country code: CA
Postal code: 92121

Securities proposed for sale

Securities proposed for sale · 1 reported row
Security	Proposed units	Aggregate market value	Units outstanding	Approximate sale date	Exchange	Broker / market maker
Common	9,520	156,032.80	32,723,877	07/01/2026	NASDAQ	Morgan Stanley Smith Barney LLC Executive Financial Services

Broker / market maker — proposed row 1, entry 1

Name: Morgan Stanley Smith Barney LLC Executive Financial Services
Street: 1 New York Plaza
Street (continued): 8th Floor
City: New York
State / country code: NY
Postal code: 10004

Acquisition of securities to be sold

Acquisition of securities to be sold · 2 reported rows
Security	Acquired	Nature of acquisition	Acquired from	Amount acquired	Gift transaction	Payment date	Nature of payment
Common	07/01/2026	Exercise of Stock Options	Issuer	5,350	N	07/01/2026	Cash
Common	05/09/2017	Restricted Stock Units	Issuer	4,170	N	05/09/2017	N/A

Sales reported in the preceding three months

Sales reported in the preceding three months · 4 reported rows
Seller	Security	Sale date	Amount sold	Gross proceeds
10b5-1 Sales for DANIEL LORRAIN	Common	06/30/2026	28,826	462,288.02
10b5-1 Sales for DANIEL LORRAIN	Common	06/01/2026	4,170	54,862.19
10b5-1 Sales for DANIEL LORRAIN	Common	05/01/2026	4,170	54,707.48
10b5-1 Sales for DANIEL LORRAIN	Common	04/06/2026	4,170	56,013.94

Seller — prior-sale row 1, entry 1

Name: 10b5-1 Sales for DANIEL LORRAIN
Street: 3565 General Atomics Court, Suite 200
City: San Diego
State / country code: CA
Postal code: 92121

Seller — prior-sale row 2, entry 1

Name: 10b5-1 Sales for DANIEL LORRAIN
Street: 3565 General Atomics Court, Suite 200
City: San Diego
State / country code: CA
Postal code: 92121

Seller — prior-sale row 3, entry 1

Name: 10b5-1 Sales for DANIEL LORRAIN
Street: 3565 General Atomics Court, Suite 200
City: San Diego
State / country code: CA
Postal code: 92121

Seller — prior-sale row 4, entry 1

Name: 10b5-1 Sales for DANIEL LORRAIN
Street: 3565 General Atomics Court, Suite 200
City: San Diego
State / country code: CA
Postal code: 92121

Prior-sale reporting

Nothing to report for the preceding three months: N

Remarks

The securities to be sold were and will be received upon the exercise of stock options over the next three months. The dates of acquisition and payment were and will be the dates of exercise/sale.

Notice signature

Notice date: 07/01/2026
Signed: /s/ Daniel Lorrain
Plan adoption dates: 09/23/2025

Company context

Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for inflammatory and fibrotic diseases with significant unmet need. PIPE-791, an LPA1 receptor antagonist, is in clinical development for idiopathic pulmonary fibrosis and chronic pain. PIPE-307 is a selective inhibitor of the M1 receptor in clinical development by Johnson & Johnson for major depressive disorder. For more information, please visit www.contineum-tx.com.

Current securities

CTNMNASDAQ · EQUITY · Current

Get the free weekly BCS email.